Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
